SCHEMBL5025815

SCHEMBL5025815

O=C(O)c1cc2cc[nH]c(=O)c2c2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
CHEK1 O14757 6/20 0.51
PARP1 P09874 2/20 0.47
NAPRT Q6XQN6 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
KEAP1 Q14145 1/20 0.42
ROCK2 O75116 1/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 2/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
ALOX12 P18054 1/20 0.40
ATIC P31939 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4287238 0.88 CHEK1 (0.48) KDM4ECHEK1PARP1NAPRTMEN1
SCHEMBL4288965 0.86 CHEK1 (0.50) KDM4ECHEK1
SCHEMBL4292052 0.82 CHEK1 (0.65) KDM4ECHEK1HPGDALDH1A1CYP2C9
SCHEMBL13659540 0.82 CHEK1 (0.73) KDM4ECHEK1PARP1MEN1KMT2A
SCHEMBL4296686 0.82 CHEK1 (0.73) KDM4ECHEK1HPGDALDH1A1CYP2C9
SCHEMBL4302533 0.82 CHEK1 (0.73) CHEK1MEN1KMT2ARXFP1
SCHEMBL4291923 0.80 CHEK1 (0.50) CHEK1
SCHEMBL4294445 0.79 CHEK1 (0.58) KDM4ECHEK1MEN1KMT2ARXFP1
SCHEMBL4300743 0.79 CHEK1 (0.49) CHEK1NAPRT
SCHEMBL4296227 0.79 CHEK1 (0.54) KDM4ECHEK1NAPRTHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
EP-1904449-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2008-04-02 EP disclosed
WO-2007008502-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258852-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, CDKN1A KDM4E 366/4885CHEK1 1/4885PARP1 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.